榴莲视频

All drugs except one remained more expensive in the U.S.

Study also showed the monoclonal antibody was noninferior to ustekinumab

"Top down" vs "step up" therapy, FDA actions, rethinking placebos, and new tulisokibart data

Elevated risk of IBD for people exposed to environmental pollutants in the prior decade

Is this the final finding from ORAL Surveillance? Don't count on it.

Greater benefit seen with higher dose of tulisokibart at week 50

Finding on HLA-DRB1*01:03 supports need for more and earlier genetic studies

Alternative designs needed, researchers caution

26% of patients receiving tulisokibart achieved clinical remission vs 1% with placebo

In trials, guselkumab more than doubled remission rates versus placebo

PREDICT-UC trial found no benefit with intensified or accelerated regimens

Infusion services and other therapies must be delivered without delay

Also in TTHealthWatch: a monoclonal antibody for ulcerative colitis